Compare VENUS REMEDIES with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs TTK HEALTHCARE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES TTK HEALTHCARE VENUS REMEDIES/
TTK HEALTHCARE
 
P/E (TTM) x -1.2 18.2 - View Chart
P/BV x 0.1 1.5 5.5% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 VENUS REMEDIES   TTK HEALTHCARE
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
TTK HEALTHCARE
Mar-19
VENUS REMEDIES/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1261,215 10.4%   
Low Rs61610 10.0%   
Sales per share (Unadj.) Rs301.8444.4 67.9%  
Earnings per share (Unadj.) Rs-24.917.2 -144.2%  
Cash flow per share (Unadj.) Rs2.527.6 9.2%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs293.3177.9 164.8%  
Shares outstanding (eoy) m12.3414.13 87.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.1 15.1%   
Avg P/E ratio x-3.852.9 -7.1%  
P/CF ratio (eoy) x36.733.0 111.3%  
Price / Book Value ratio x0.35.1 6.2%  
Dividend payout %029.0 0.0%   
Avg Mkt Cap Rs m1,15412,894 8.9%   
No. of employees `0000.92.3 40.0%   
Total wages/salary Rs m3931,307 30.1%   
Avg. sales/employee Rs Th4,026.12,715.7 148.2%   
Avg. wages/employee Rs Th425.0565.3 75.2%   
Avg. net profit/employee Rs Th-331.8105.4 -314.8%   
INCOME DATA
Net Sales Rs m3,7246,279 59.3%  
Other income Rs m2378 29.0%   
Total revenues Rs m3,7476,356 58.9%   
Gross profit Rs m395496 79.7%  
Depreciation Rs m338147 230.6%   
Interest Rs m35434 1,048.2%   
Profit before tax Rs m-275393 -70.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32149 21.2%   
Profit after tax Rs m-307244 -125.9%  
Gross profit margin %10.67.9 134.3%  
Effective tax rate %-11.537.9 -30.3%   
Net profit margin %-8.23.9 -212.3%  
BALANCE SHEET DATA
Current assets Rs m2,6382,717 97.1%   
Current liabilities Rs m2,3051,571 146.7%   
Net working cap to sales %8.918.3 49.0%  
Current ratio x1.11.7 66.2%  
Inventory Days Days13532 421.2%  
Debtors Days Days4647 99.3%  
Net fixed assets Rs m4,871991 491.5%   
Share capital Rs m123141 87.3%   
"Free" reserves Rs m3,4962,373 147.3%   
Net worth Rs m3,6192,514 143.9%   
Long term debt Rs m1,3743 40,423.5%   
Total assets Rs m7,5094,158 180.6%  
Interest coverage x0.212.6 1.8%   
Debt to equity ratio x0.40 28,083.5%  
Sales to assets ratio x0.51.5 32.8%   
Return on assets %0.66.7 9.5%  
Return on equity %-8.59.7 -87.5%  
Return on capital %1.616.9 9.3%  
Exports to sales %03.6 0.0%   
Imports to sales %13.90.5 2,813.8%   
Exports (fob) Rs mNA225 0.0%   
Imports (cif) Rs m51731 1,668.9%   
Fx inflow Rs m0225 0.0%   
Fx outflow Rs m51771 726.3%   
Net fx Rs m-517154 -335.2%   
CASH FLOW
From Operations Rs m514173 297.2%  
From Investments Rs m-12397 -127.6%  
From Financial Activity Rs m-387-307 126.0%  
Net Cashflow Rs m4-38 -11.1%  

Share Holding

Indian Promoters % 32.9 65.4 50.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 3.7 4.9%  
FIIs % 0.6 5.2 11.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 25.8 257.4%  
Shareholders   20,121 12,723 158.1%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   CADILA HEALTHCARE  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling Pressure, Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

Indian share markets closed on a negative note yesterday amid weak global cues and disappointing domestic factory output data.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

TTK HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS